GRAIL, Inc., a commercial-stage healthcare company, focuses on developing technologies for early cancer detection in the United States and internationally. It provides Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company offers development services including support for ongoing clinical studies, pilot testing, research, and therapy development. It also develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

GRAIL, Inc.

There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on GRAIL Inc (GRAL) and SanDisk Corp (SNDK) with bullish sentim...

Analysts Offer Insights on NA Companies: GRAIL Inc (GRAL) and SanDisk Corp (SNDK)

Guggenheim analyst Subbu Nambi reiterated a Buy rating on GRAIL Inc yesterday and set a price target of $75.00. The company’s shares closed yesterd...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GRAL	$69.48	+9.59%	1.64M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GRAL	$69.48	+9.6%	1.64M
3
4
5
6

GRAL

GRAL

Get GRAIL, Inc. Data in Excel

Get GRAIL, Inc. Data in Excel